Glucocorticoid Doses and Acute-Phase Reactants at Giant Cell Arteritis Flare in a Randomized Trial of Tocilizumab

Arthritis and Rheumatology - United Kingdom
doi 10.1002/art.40876
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Wiley

Related search

Design of the Tocilizumab in Giant Cell Arteritis Trial

International Journal of Rheumatology
RheumatologyImmunology
2013English

Giant Cell Arteritis.

Journal of Clinical Pathology
MedicineForensic MedicinePathology
1991English

Healthcare Costs of Potential Glucocorticoid-Associated Adverse Events in Patients With Giant Cell Arteritis

ClinicoEconomics and Outcomes Research
Health PolicyEconomicsEconometricsFinance
2019English

Psy44 - Tocilizumab in Combination With Corticosteroids for the Treatment of Giant Cell Arteritis: A Budget Impact Analysis in Italy

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

THU0340 Adrenal Insufficiency During Glucocorticoid Treatment in Patients With Polymyalgia Reumatica or Giant Cell Arteritis

2017English

Internuclear Ophthalmoplegia in Giant Cell Arteritis.

Journal of Neurology, Neurosurgery and Psychiatry
PsychiatryMental HealthNeurologySurgery
1992English

Giant-Cell Arteritis and Polymyalgia Rheumatica

Annals of Internal Medicine
Internal MedicineMedicine
2003English

Giant Cell Arteritis: Authors' Reply

BMJ
1992English

Psy108 - Cost-Utility Analysis of Tocilizumab in Combination With Corticosteroids for the Treatment of Giant Cell Arteritis in Italian Patients

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy